Nicole Lambert - 25 Sep 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
Signature
By: Nathan A. Smith For: Nicole Lambert
Issuer symbol
MYGN
Transactions as of
25 Sep 2021
Net transactions value
-$492,536
Form type
4
Filing time
27 Sep 2021, 21:13:55 UTC
Previous filing
23 Sep 2021
Next filing
04 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Tax liability $43,669 -1,311 -0.68% $33.31 191,610 25 Sep 2021 Direct F1
transaction MYGN Common Stock Tax liability $114,120 -3,426 -1.8% $33.31 188,184 26 Sep 2021 Direct F1
transaction MYGN Common Stock Sale $334,747 -10,112 -5.4% $33.10 178,072 27 Sep 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.
F2 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.43 to $33.62, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.